Soligenix awarded contract to develop ricin vaccine, technology

The National Institutes of Health awarded a $24.7 millon contract on Friday to Soligenix, Inc., to advance the development of a thermostabilization technology, which can prevent the effects of ricin exposure when combined with the company’s ricin toxin vaccine Rivax.

Ricin exposure can lead to local tissue necrosis and general organ failure. Death usually occurs a few days after exposure.

Soligenix is developing the RiVax vaccine in hopes that it can be used in rapid deployment in the event of a biological attack. It may also deter the use of ricin as a biological weapon.

The World Health Organization reports, however, that 50 percent of all global vaccine doses are wasted because they are not kept within required temperature ranges. The distribution and storage of a vaccine such as Rivax currently has a cold chain requirement.

Soligenix's ThermoVax technology is designed to produce temperature stabilization of potent vaccines.

Several contract options can extend the 16-month contract award up to six years. If the entire contract is excised, it will support the preclinical, manufacturing and clinical development necessary to advance RiVax with the Food and Drug Administration.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.